- Home
- ESP vs AVTX Comparison
ESP vs AVTX Comparison
Compare ESP & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESP | AVTX |
|---|---|---|
| Founded | 1928 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.8M | 248.3M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | ESP | AVTX |
|---|---|---|
| Price | $43.82 | $18.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $30.14 |
| AVG Volume (30 Days) | 15.8K | ★ 354.7K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | ★ 28.72 | N/A |
| EPS | ★ 3.16 | N/A |
| Revenue | ★ $42,600,530.00 | $192,000.00 |
| Revenue This Year | $9.16 | N/A |
| Revenue Next Year | $5.68 | N/A |
| P/E Ratio | $13.74 | ★ N/A |
| Revenue Growth | ★ 4.90 | N/A |
| 52 Week Low | $24.85 | $3.39 |
| 52 Week High | $55.00 | $20.72 |
Technical Indicators
Market Signals| Indicator | ESP | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 68.93 | 55.12 |
| Support Level | $41.30 | $15.53 |
| Resistance Level | $44.30 | $20.72 |
| Average True Range (ATR) | 1.69 | 1.47 |
| MACD | 0.52 | 0.08 |
| Stochastic Oscillator | 87.89 | 59.44 |
Price Performance
Historical ComparisonAbout ESP Espey Mfg. & Electronics Corp.
Espey Manufacturing & Electronics Corp designs, develops, tests, and manufactures specialized military and rugged industrial power supplies and transformers for use in harsh or severe environment applications. Its products and solutions include power converters, power conditioning, high-voltage radar, contract manufacturing, custom engineering, and others. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).